This pharma company was founded more than 10 years ago and is focused in full-service CRO with specialization on oncology. This CRO company is looking for an opportunity to merge with a larger CRO covering the European or North American region.
The company is based in Northern Europe is focused on full-service CRO with specialization in oncology. The company has presence in more than 12 countries worldwide and have about 50 employees. Since the company’s foundation, it has shown a stable growth with over 250 clinical trials and consulting projects completed. At present, the company manages 6 ongoing trials and has a promising pipeline with more than 11 million Euro revenue.
Contact us to get details about this company for sale
This European CRO company is an innovative company focused on full-service CRO. The main focus is oncology, but the company also has studies in cardiology, gastroenterology, endocrinology, orphan diseases mostly in Phases II and III.
Feel free to contact us for more information regarding this Oncology clinical trials provider Eastern Europe for sale. If this pharma company for sale does not fit your requirements feel free to ask for other companies from pharma business in the section pharmaceutical companies for sale. For a review of pharma buyers please visit section pharmaceutical companies wanted.
Note: CFIE only works with formal companies. We do get a lot of requests and it is difficult to follow up on all inquiries from visitors to our website. For each company, we assess the likelihood of a future transaction. We only get back to you if we see a realistic opportunity to do a future acquisition or business sale. In order to increase your chances of receiving a reply as an individual, please explain as much as possible about your personal background, strategy and fit with the target. There is also a possibility that your details will be kept on file and we will get back to you once there is an opportunity to do a transaction. CFIE can’t guarantee you will receive an answer to your request.